The DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index.
Trends in kinase drug discovery: targets, indications and inhibitor design
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Keys, J. R., Land vatter, S. W., et al. (1994) · Nature · doi:10.1038/372739a0 · Cited by 3,288
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Trends in GPCR drug discovery: new agents, targets and indications
Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B., & Gloriam, D. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.178 · Cited by 2,627
Self-citationClinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Staurosporine, a potent inhibitor of phospholipidCa++dependent protein kinase
Tamaoki, T., Nomoto, H., Takahashi, I., Kato, Y., Morimoto, M., & Tomita, F. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(86)90008-2 · Cited by 2,452
Research works printed but not linked: 10
- Jürg Zimmermann. Interview with Jürg Zimmermann, global head of oncology & exploratory chemistry at Novartis. Future Med. Chem. 1, 1395–1398 (2009). · doi:10.4155/fmc.09.115
- Fabbro, D. in Inhibitors of Protein Kinases and Protein Phosphates (eds Pinna, L. A. & Cohen, P. T. W.) 361–389 (Springer, 2005).
- Zhang, Q., Zheng, P. & Zhu, W. Research progress of small molecule VEGFR/c-met inhibitors as anticancer agents (2016-present). Molecules 25, 2666 (2020). · doi:10.3390/molecules25112666
- Vu, P. & Patel, S. P. Non-small cell lung cancer targetable mutations: present and future. Precis. Cancer Med. https://doi.org/10.21037/pcm.2019.11.03 (2020). · doi:10.21037/pcm.2019.11.03
- Looney, A.-M., Nawaz, K. & Webster, R. M. Tumour-agnostic therapies. Nat. Rev. Drug Discov. 19, 383–384 (2020). · doi:10.1038/d41573-020-00015-1
- Ekambaram, R. et al. Selective bisubstrate inhibitors with sub-nanomolar affinity for protein kinase Pim-1. ChemMedChem 8, 909–913 (2013). · doi:10.1002/cmdc.201300042
- Dubost, C. Primary hyperparathyroidism: the surgical problems. A study of 1,300 operated patients. Horm. Res. 32, 101–103 (1989). · doi:10.1159/000181267
- Scior, T., Domeyer, D. M., Cuanalo-Contreras, K. & Laufer, S. A. Pharmacophore design of p38α MAP kinase inhibitors with either 2,4,5-trisubstituted or 1,2,4,5-tetrasubstituted imidazole scaffold. Curr. Med. Chem. 18, 1526–1539 (2011). · doi:10.2174/092986711795328409
- Lorusso, P. et al. First-in-human study of the monopolar spindle 1 (Mps1) kinase inhibitor BAY 1161909 in combination with paclitaxel in subjects with advanced malignancies. Ann. Oncol. 29, viii138 (2018). · doi:10.1093/annonc/mdy279.410
- Mauro, M. J. et al. A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs). J. Clin. Oncol. 37, TPS7070–TPS7070 (2019). · doi:10.1200/jco.2019.37.15_suppl.tps7070
Cited by
The next-generation Open Targets Platform: reimagined, redesigned, rebuilt
Ochoa, D., Hercules, A., Carmona, M., Suveges, D., Baker, J., Malangone, C., Lopez, I., Miranda, A., Cruz-Castillo, C., Fumis, L., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac1046 · Cited by 432
Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update
Roskoski, R. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2022.106552 · Cited by 273
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 265
The IUPHAR/BPS Guide to PHARMACOLOGY in 2024
Harding, S. D., Armstrong, J. F., Faccenda, E., Southan, C., Alexander, S. P. H., Davenport, A. P., Spedding, M., & Davies, J. A. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkad944 · Cited by 226
Nazarova, V. A., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1066988 · Cited by 111
Self-citation
Metadata
- Authors
- Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2021-08-05
- Volume
- 20
- Issue
- 11
- Pages
- 839-861
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W3189949217
- Cited by
- 779
- References
- 240
- FWCI
- 29.57
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-09-02)
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trends in kinase drug discovery: targets, indications and inhibitor design. https://app.cochat.ai/papers/10.1038/s41573-021-00252-y
- The paper
- Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021). Trends in kinase drug discovery: targets, indications and inhibitor design. Nature Reviews Drug Discovery. https://doi.org/10.1038/s41573-021-00252-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.